Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials
about
Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerCombination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experienceSalvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyFrom Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.Urothelial carcinoma management in elderly or unfit patients.Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysisImproved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial CarcinomaThe impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Circulating Biomarkers in Bladder Cancer.Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experienceSecond-line systemic therapy for metastatic urothelial carcinoma of the bladder.Emerging drugs for urothelial carcinoma.Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB AlterationsAn open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.Reply to S. Buti and S. Culine.[Systemic therapy of metastatic bladder cancer.]A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study.Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan
P2860
Q30964757-17197B7E-7066-4A67-A511-6C54D1976116Q33412123-803EE85D-5D8A-4918-A8F2-A83BCB78698FQ33418868-3677A397-4BFF-4626-805D-03FAE845DFC3Q33426694-06AB5BE0-4DFC-48A2-A60B-E88217B97161Q33919252-57BA3ABF-6A7A-459E-B39F-FB2798BCDEE2Q35180823-B0CDC33C-FDB5-45BA-9D44-7D71BBEE924EQ35586693-56A3B03F-7E3F-49C4-8BF4-9D6774511584Q35586740-DFA298EB-17D6-43A7-A40E-BDBA2A9D7B82Q35771672-91B2797E-5359-4978-9172-6DA7BBF3770FQ36859124-B65C4B6D-DD7D-47BA-99A4-ADF49000F969Q37030514-46758AF8-38F3-4F17-B399-785CA946584FQ37108266-2536DCB8-4F5D-41CE-AF07-3881E6E90350Q37261102-73720D1F-5364-459C-86AC-C39083B77E47Q37323009-D1EBBE98-B5D1-48C0-9D24-84A51A18B270Q37475193-3AD087D9-2F05-4B0F-8163-1B5F0B060FC0Q37530401-81DBE112-ADE8-4919-AB15-39FBB043CA70Q37665453-98819A3B-F9DB-4087-9E96-895B1C08281FQ38155201-DC02655A-DDEF-40EA-9079-B5121F4AC704Q38160271-6D8052D8-2DED-42FC-81B8-91802954D7C9Q38612831-AD72277D-7F15-455E-8CAF-5065625CA462Q38798645-4117329A-0F2C-42EA-82B7-5E11BF41871DQ39325143-2C01FDEE-3C5D-4C87-92EE-06FBB20E2AB9Q39863683-A0722C2E-0711-4068-B18D-10CCD93CFE5DQ40912134-0FE7FF75-A403-45C8-9604-D8ABC5372234Q41979947-1C86B096-6F26-4BF1-B5D6-BED404B4440FQ43196463-FA08920D-3C5D-4587-B0EB-9462FB2D105BQ44419809-5B594941-E6BE-4DAA-BEB0-ED099955C0F2Q46311055-57E0BA26-649F-4481-AA19-A610B6649E5DQ47094005-AAD72B50-59AE-470E-BBBB-0913F1564857Q57173019-0E7E1681-51EB-4B67-AE48-23697A0DB1FB
P2860
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@ast
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@en
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@nl
type
label
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@ast
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@en
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@nl
prefLabel
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@ast
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@en
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@nl
P2093
P2860
P3181
P1433
P1476
Time from prior chemotherapy e ...... ed, prospective phase 2 trials
@en
P2093
Angela Q Qu
Awais Khan
Cora N Sternberg
Daniel P Petrylak
David J Vaughn
Gregory R Pond
Guru Sonpavde
Joaquim Bellmunt
Jonathan E Rosenberg
Matthew D Galsky
P2860
P304
P3181
P356
10.1016/J.EURURO.2012.11.042
P407
P577
2013-04-01T00:00:00Z